Lupin Dental raises €15M Series A to bring supervised robotic tooth preparation to market

Lupin Dental (Montpellier) has closed a €15 million Series A led by Fynveur, which invested €10 million as the anchor. Existing shareholders and private investors contributed the remainder; the round was complemented by a loan from Bpifrance — a non-dilutive credit facility that French public investment banks extend selectively to companies with demonstrated technical progress. Invus, the US-based private investment firm advising Fynveur on this transaction, will join Lupin Dental's board alongside Fynveur. The company was founded in 2019 by Dr. Galip Gürel and Dr. Stefen Koubi.

Lupin Dental's product is the Lupin Robotic System: a supervised automated robotic platform for minimally invasive tooth preparation for aesthetic veneers. The system has two components. A software suite designs the patient's final smile and generates a tooth preparation plan from that design. The robotic workstation then executes that plan precisely — the dentist supervises, but the instrument path is controlled by the machine. The pitch is procedural consistency: veneer tooth preparation freehand is a technique-sensitive step where outcome quality varies significantly across operators. A supervised robot makes that step reproducible.

The regulatory map

Lupin Dental received UKCA certification in June 2026, authorising commercialisation in Great Britain, and holds prior clearance in India. The company does not currently hold regulatory approval for clinical use in the EU or the US — two markets that would define whether this is a continental platform or a niche device.

The EU MDR pathway for a Class IIa or Class III active surgical device (which this almost certainly qualifies as) is among the more demanding regulatory processes in medical devices. Timeline to approval, if sought now, is realistically 18–36 months depending on notified body capacity and the completeness of the clinical evidence package. US FDA clearance under 510(k) or De Novo would run on a parallel, similarly lengthy timeline.

This means the capital from the Series A is going primarily toward building the clinical and regulatory evidence, not toward commercial scale — at least in the company's natural markets. The UK market is open, India is open; EU and US require more work.

Board and investors

Michel Mayer — former Chairman and CEO of Freescale Semiconductor, a Motorola spin-out — chairs the board. Philippe Veran, founder of Biotech Dental (one of France's leading dental implant and aligner manufacturers), is a board member. Veran's presence on the board is notable: Biotech Dental has distribution across European dental chains, and his network inside the professional dental industry is a potential commercial channel once EU clearance arrives.

Fynveur is a long-term private equity firm; its advising relationship with Invus — which has a track record in healthcare and consumer companies — brings US commercial networks onto the board at a stage where FDA is not yet in scope but will matter.

"Lupin Dental opens a new chapter with this important milestone. It reflects our investors' confidence in our vision and enables us to accelerate our mission to transform dental care through innovation," said Dr. Gürel and Dr. Koubi.

The next 18 months are a regulatory chapter. Commercialisation at scale in Europe and North America follows the EU MDR and FDA decisions, not this cheque.